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Background: Although polyvascular disease is a predictor of future ischemic events, long-term antiplatelet therapy after coronary stenting is not 
well established in terms of the secondary prevention of systemic vascular diseases. We performed a clinical randomized trial to evaluate the effect 
of cilostazol in patients undergoing coronary stent placement with and without prior cerebral infarction.
methods: A total of 307 patients who had undergone coronary stent implantation more than 6 months previously were randomly assigned to 
receive cilostazol plus aspirin therapy (cilostazol group, n=152) or aspirin monotherapy (aspirin group, n=155) after completion of dual antiplatelet 
therapy with aspirin and a thienopyridine. The primary efficacy endpoint was a composite of death, myocardial infarction, cerebral infarction, or 
coronary or cerebrovascular revascularization at 2 years after randomization. The primary safety endpoint was major or minor bleeding.
results: The patients had a mean age of 68 years, and 72% were men. At 2 years, follow-up clinical data were available for 98% of patients. The 
primary efficacy endpoint occurred in 11.6% of patients in the cilostazol group and 20.1% of patients in the aspirin group (hazard ratio [HR], 0.55; 
95% confidence interval [CI], 0.30 to 0.99; P=0.047). Among patients with prior cerebral infarction, the event rate was significantly lower in the 
cilostazol group than in the aspirin group (17.2% versus 35.1%; HR, 0.41; 95% CI, 0.19 to 0.88; P=0.022), whereas among patients without prior 
cerebral infarction, there was no significant difference between the groups (8.0% and 11.3%, respectively; HR, 0.72; 95% CI, 0.28 to 1.86; P=0.50). 
The primary safety endpoint was similar between the cilostazol group and the aspirin group (2.7% and 4.5%, respectively; HR, 0.59; 95% CI, 0.17 to 
2.02; P=0.40).
conclusions: Among patients with coronary stent implantation, the addition of cilostazol to aspirin reduced the incidence of cardiac and 
cerebrovascular events at 2 years. The impact of cilostazol was more prominent in patients with prior cerebral infarction than without prior cerebral 
infarction. 
